Don't they deserve some sage advice too? The following would be appropriate now IMHO:
Encore Investment Analytics Inc makes cautious comments on Sarepta short position. With 40% of stock now short, short sellers risk major losses on any further positive indications regarding FDA AA request. Expected inclusion of SRPT in Russell 2000 index provides further major risk to short view. Recommend reducing short position ahead of any positive catalysts.